Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.

M J McQueen¹, E Lonn, H C Gerstein

¹Hamilton Regional Laboratory Medicine Program, Department of Laboratory Medicine, St. Joseph's Hospital, Hamilton, Ontario. mcquemat@hhsc.ca

Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum

|August 23, 2005

Summary

The HOPE study found that Ramipril, an ACE-inhibitor, significantly reduced cardiovascular events in high-risk individuals. Benefits were observed across diverse subgroups, including those with diabetes, highlighting Ramipril

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study.

Journal of cardiac failure·2023

Same author

Vitamin D and progression of carotid intima-media thickness in HIV-positive Canadians.

HIV medicine·2017

Same author

What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts.

International journal of obesity (2005)·2015

Same author

Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population.

Translational psychiatry·2015

Same author

Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.

Journal of internal medicine·2015

Same author

Myocardial vacuolization, a marker of ischemic injury, in surveillance cardiac biopsies posttransplant: Correlations with morphologic vascular disease and endothelial dysfunction.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015

Area of Science:

Cardiovascular Medicine
Clinical Trials
Pharmacology

Background:

The HOPE (Heart Outcomes Prevention Evaluation) study investigated interventions for cardiovascular disease prevention.
High-risk populations, including those with diabetes, often face increased cardiovascular event risks.

Purpose of the Study:

To evaluate the efficacy of Ramipril (an ACE-inhibitor) and Vitamin E in reducing cardiovascular events.
To determine if Ramipril offers benefits across various patient subgroups and risk factors.

Main Methods:

A prospective, randomized, multinational trial involving a high-risk population.
Participants received either Ramipril, Vitamin E, or placebo.

Main Results:

Related Experiment Videos

Ramipril significantly reduced the risk of future cardiovascular events, irrespective of diabetes status, hypertension, or existing cardiovascular disease.

Vitamin E did not show a significant effect on cardiovascular event risk.

Ramipril demonstrated benefits in patients with renal insufficiency and reduced new-onset diabetes.

Conclusions:

Ramipril is a safe and cost-effective treatment for high-risk individuals to prevent cardiovascular events.
The ACE-inhibitor Ramipril offers broad micro- and macrovascular benefits, including in patients with diabetes and renal insufficiency.